Therapeutic Drug Monitoring Market Synopsis

Therapeutic Drug Monitoring Market Size Was Valued at USD  2.40 Billion in 2023 and is Projected to Reach USD  3.48 Billion by 2032, Growing at a CAGR of 4.20% From 2024-2032.

Therapeutic Drug Monitoring therefore involves the determination of certain drug at some fixed time intervals in the patient’s plasma to determine whether the required concentration has been achieved. It aims to improve the probability of achieving the optimum therapeutic outcome with a given drug at the patient level on the one hand and minimize toxicity of a drug especially where the drug has a small therapeutic window or pharmacokinetic variability.

• Therapeutic Drug Monitoring (TDM) market is highly significant for achieving the optimal pharmacotherapy goals because it ensures that the concentration of the therapeutic agent in the body of a patient is appropriate and safe and thus efficient and effective. This approach is especially important in the drugs where the difference between effective dose and toxic dose is small like in antiepileptic, anticoagulant, immunosuppressant drugs. This is because chronic diseases are common and more patient groups on medication require TDM services due to their complicated dosing regimens. NIH of the USA also emphasizes on the fact that TDM is needed to enhance the result of patients since it incorporates the response to the drug. Consequently, the implementation of the TDM practices in strategies of clinical medicine has been gradually advanced by various healthcare providers, which will in turn contribute to the growth of the market.
• The global TDM market faces innovations in the analytic methods and equipment such as LC-MS/MS and immunoassays to increase the precision and effectiveness of drug concentration. The TDM has also been enhanced by Point of care technologies for instance point of care testing devices that give fast and fast therapeutic determination most especially in the emergency units and Intensive care units. Also, because of increased attention for Precision Medicine, there is increased emphasis on the sub-discipline of pharmacogenomics, or how genetic variation in patients impacts their reactivity to the drugs. Thus, as viewed in TDM and pharmacogenomic information deployed in the systems of healthcare practitioners, dosing regimens could be optimized according to the patient’s genotype to enhance therapeutic positivity. The synergy that the integration of TDM with pharmacogenomics brings is expected to boost the market potentiality as the combination is expected to provide more optimised techniques for the monitoring and the personalised therapies for the drugs.
• Thus, the market share of TDM in the regions is distributed as follows: The highest – in North America, due to the trend towards the growth of chronic diseases, the availability of developed healthcare, and above-average investments in R&D. The presence of big players within the region is part of the market driving force as these companies are always developing and diversifying their products. The Asia Pacific region is anticipated to experience the highest growth chiefly in terms of the growing global health care expenditure, rising health care parity, and the focus on Precision Medicine. United States has adopted acts that enable health care organizations to improve their healthcare delivery, other nations such as India and China are embracing policies that encourage innovation in healthcare delivery thus equally boosting TDM services. Moreover, utilizing EHR in clinical practice has a positive effect on TDM as integrated into EHR in patient treating.
• The market of TDM has possible obstacles that are academic and legal as well as imposing testing procedures. One has to understand that standard deviations in laboratories in terms of practices and methodologies applied to obtain the drug levels vary and, therefore, may not allow arriving at accurate decisions in clinical practice. Besides, TDM requires high costs to embrace advanced Technological devices, this may be a problem mostly to the organizations that might have limited capital. However, the market is still very promising because the technology is still growing steadily in the field, there is enhanced awareness by the medical professionals of TDM and its significance, and the emerging trend of personalized medicine. Consequently, TDM shall remain a component of the further advancements of modern medicine; thereby increasing the relevance and need for raising the impact of outcomes for patient status and treatment effectiveness enhancement.
• Therefore, the conclusion that can be done is that the market of TDM is expanding because of shift from the traditional approaches in medicine towards more individualized, evolving analytical methods as well as pharmacogenomics which is becoming integrated in healthcare. New opportunities for point-of-care testing as well as further regulatory backing for innovative monitoring solutions will continue to increase the market potential of TDM into the future, thereby guaranteeing that patients receive the proper pharmacotherapy adjusted to their requirement.

Therapeutic Drug Monitoring Market Trend Analysis

Increased Adoption of Personalized Medicine

• The drugs in the market for therapy personalized medicine therapeutic drug monitoring is experiencing high demand from consumer due to the rising focus for identity treatment options for patients. It also increases the efficiency of the treatment, additionally, it reduces the chance of the patient experiencing an adverse effect from a drug interaction because the doses of the medication will then be prescribed according to the patient’s genetic code, metabolism, and disease state. Examining the shift from volume to value in healthcare, PM is different in a more formal approach of managing long-term conditions like cancer care management or chronic pain management among trop others. The selection of drugs and dosage adjustments due to the integration of newest diagnostic facilities for pharmacogenomics and biomarker testing also add up to this change.
• Moreover, the increasing frequency of chronic diseases and related health care conditions that require the use of therapeutic drugs has also created pressure for individualized tracking systems. This trend is now apparent, and represents how healthcare workers are starting to move away from the ‘one-size-fits-all’ approach to dosing, and looking for more individualised. Mobile health applications and wearable devices are allowing real time monitoring of drug levels and the reaction or response of patients to the medication they are taking, improving both patient involvement and compliance. The market is predicted to grow at a rapid pace once the regulatory bodies and payers get involved in support of personalized medicine due to the availability of greater opportunities for the growth and development for pharmaceutical firms and healthcare centers that would make important changes to the provision of medical profiles.

Advancements in Point-of-Care Testing

• The PDOCT for TDM market has experienced important developments due to technological progress and despite the ongoing problems, due to the demand for tailored medicine. Furthermore, there has been advances in technology whereby organizations have come up with portable, easy to use tools that can quickly determine the drug level in the patient and this is done right at the patient’s corner which makes the patient to adhere to the treatment thus improving their health status. progresses in microfluidic technology and biosensing that improved sensitivity and selectivity allowed expanding the range of therapeutic drugs to be tracked. Along this line, integration with delivery e-health systems ensures the real-time data exchange with the healthcare providers for the dosage adjustments’ purposes, as well as the improvement of the patient handling.
• In fact, currentreece is completely legal to use POCT in TDM, and there is the pressure to bring on the market products that meet extremely high quality requirements. Another reason of such type of relation is concerned with changes in dependence towards the concept of value-based care and increased need for POCT for TDM due to both a reduced number of visits of the hospital in question and more appropriate treatment regimes. In light of growing emphasis by healthcare providers in the value of immediate results to optimize therapeutic outcomes, more research and development are expected to be directed to this field. Therefore, coordination of POCT for TDM does form a significant segment of healthcare technology in the current society especially when a prescription drug concentration is put under intense scrutiny.

Therapeutic Drug Monitoring Market Segment Analysis:

Therapeutic Drug Monitoring Market Segmented based on  Technology,Product , Drug Class and End User.

By Technology, Immunoassays  segment is expected to dominate the market during the forecast period

• The Therapeutic Drug Monitoring (TDM) Market is more influenced by such factors because it has always benefited from the developments in different technologies that improve the evaluation of drugs’ levels in the patient’s body. This is because immunosays are typically selective and sensitive in identifying different quantities of several drugs and their respective metabolites in body fluids. These assays are essential in management of medications that have depth of therapeutic range and these include antiepileptics and antidepressants among others to ensure patients receive therapeutic doses with very low risk of toxicity. The availability of new, high speed diagnostic methods is also useful in ordering the clinic, contributing to optimizing the result of therapeutic interventions.
• Similarly, the use of chromatography integrated with spectrometry seems to be becoming more preferred in the TDM Market because of its higher resolution and compatibility with complex biological samples. Some advantages that come with this technology include the ability to determine the concentration of not only the drugs in a patient but also the technology’s metabolites thus giving a complete view of the pharmacokinetic profile of the patient. In addition, steady improvement in mass spectrometry–based techniques, specifically when combined with HPLC, has significantly improved the accuracy of TDM due to its ability to quickly and accurately identify drug concentrations. Implementation of these technologies in clinical laboratories enhance the monitoring capacity apart from promoting personalized medicine approach thereby fueling the TDM Market growth that aligns with the global healthcare systems’ objective of enhancing therapeutic efficacies.

By Drug Class, Antiepileptic Drugs segment held the largest share in 2023

• Since TDM has shifted to a critical measure in contemporary healthcare frameworks for pharma in general, along with the classes of drugs aforementioned, it becomes a variable that enhances the efficacy of the treatment and the therapeutic results for patients. This is probably well illustrated by antiepilectic drugs wherein it is actually desirable to ensure that the concentration of the drug in the plasma is kept well below a certain threshold so as to avoid ‘seizures on’, while at the same time endeavouring to prevent ‘seizures off’. Like antiepileptic, antiarrhythmic drugs also require TDM due to their very low therapeutic window and risk of cardiac adverse effects if the dosage are not well controlled. Another category of vital drugs in treatment of transplant patients and autoimmune conditions is immunosuppressants similar to the other drugs rely on TDM to avails rejection and secure a positive result. The increasing understanding of the value of TDM in personalized medicine across these therapeutic areas is likely the major factor that will continue to fuel the demand for more specialized TDM services.
• Apart from these specific drug classes, there are many other drugs that fall under the “Others” segment in the TDM Market which require monitoring and therefore represents more market opportunity. This includes a variety of drugs where efficacy for a particular patient may differ greatly depending on particular genes, other diseases, or other drugs the patient is on. Therefore, further development of the concept of ‘personalised medicine’ within the sphere of healthcare management, with an emphasis on certain therapeutic approaches regarding particular patients, makes the substantiated processes of TDM all the more important. Other enhancements such as the high through put screening method, capability of data analysis in the laboratories would add value to the efficiency of TDM, this comes along side as a plus to the quality of treatment being provided to the patient in addition to the general efficiency of the health care system. Indeed a combination of factors such as availability of technology support for clinical practice, backing from the government and a growing concern for patient safety propels the market further.

Therapeutic Drug Monitoring Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• The Therapeutic Drug Monitoring (TDM) Market in Asia Pacific region is expected to exhibit high growth in forecast period, mainly due to millennial patient’s population, rise in chronic diseases and the growing adoption of personalized medicine. As healthcare organizations in China, India, and Japan progress towards medical modernisation, the need for optimisation of drug therapy has also grown. It also makes it easier to assess the amount of the drug that is currently in the patient systemic circulation and other helps in the change of the dosage and also preventing the undesirable bad impact. Population in the region supports the adoption of TDM practices while improvement in health care equipment increase effectiveness of the intervention for diseases such as cancer, cardiovascular diseases, and mental health diseases.
• Moreover, Asia Pacific continues to be a large market with high spending on the development of new and improved TDM solutions. Another type of factor that can be stated as a driving force for the constant increase in the growth rate of TDM market is the increased attention of healthcare organizations & practitioners to the services of TDM as a valuable assistant in enhancing the therapeutic effectiveness of the therapeutic processes. Furthermore, better relations between pharmaceutical firms and diagnostic laboratories have improved the provision of superior TDM testing services. As for the TDM services, Asia Pacific holds the largest share of the global TDM market due to its concentration on precision medicine and effective organization of drug management; however, due to the specifics of regional legislation, doing business there can be extremely challenging for both residents and foreign investors, although the potential for development is undeniable.

Active Key Players in the Therapeutic Drug Monitoring Market

• Abbott (USA)
• ALPCO (USA)
• Beckman Coulter, Inc (USA)
• Bio-Rad Laboratories, Inc (USA)
• Thermo Fisher Scientific Inc. (USA)
• Chromsystems Instruments & Chemicals GmbH (Germany)
• F.Hoffmann-La Roche Ltd. (Switzerland)
• Randox laboratories Ltd (UK)
• Siemens Healthineers AG (Germany)
• biomérieux, Inc. (France)
• Others Key Player

Key Industry Developments in the Therapeutic Drug Monitoring Market

• In April 2024, Ferring B.V. announced the launch of Rebyota and Adstiladrin in the U.S., providing major long-term opportunities for the company to grow in the therapeutics drugs segment.
• In July 2023, Beckman Coulter announced the Dxl 9000 Access Immunoassay Analyzer to meet the clinical laboratories' requirement for fast, reliable, and improved quality of menu expansion.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Therapeutic Drug Monitoring Market by Technology
 4.1 Therapeutic Drug Monitoring Market Snapshot and Growth Engine
 4.2 Therapeutic Drug Monitoring Market Overview
 4.3 Immunoassays
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Immunoassays: Geographic Segmentation Analysis
 4.4 Chromatography-Spectrometry
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Chromatography-Spectrometry: Geographic Segmentation Analysis
 4.5 Others
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Others: Geographic Segmentation Analysis

Chapter 5: Therapeutic Drug Monitoring Market by Product
 5.1 Therapeutic Drug Monitoring Market Snapshot and Growth Engine
 5.2 Therapeutic Drug Monitoring Market Overview
 5.3 Consumables
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Consumables: Geographic Segmentation Analysis
 5.4 Equipment
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Equipment: Geographic Segmentation Analysis

Chapter 6: Therapeutic Drug Monitoring Market by Drug Class
 6.1 Therapeutic Drug Monitoring Market Snapshot and Growth Engine
 6.2 Therapeutic Drug Monitoring Market Overview
 6.3 Antiepileptic Drugs
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Antiepileptic Drugs: Geographic Segmentation Analysis
 6.4 Antiarrhythmic Drugs
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Antiarrhythmic Drugs: Geographic Segmentation Analysis
 6.5 Immunosuppressant Drugs
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Immunosuppressant Drugs: Geographic Segmentation Analysis
 6.6 Antibiotic Drugs
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Antibiotic Drugs: Geographic Segmentation Analysis
 6.7 Others
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Others: Geographic Segmentation Analysis

Chapter 7: Therapeutic Drug Monitoring Market by End Users
 7.1 Therapeutic Drug Monitoring Market Snapshot and Growth Engine
 7.2 Therapeutic Drug Monitoring Market Overview
 7.3 Hospital
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospital: Geographic Segmentation Analysis
 7.4 Diagnostic labs
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Diagnostic labs: Geographic Segmentation Analysis
 7.5 Research & Academic Institutes
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Research & Academic Institutes: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Therapeutic Drug Monitoring Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 ABBOTT (USA)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 ALPCO (USA)
 8.4 BECKMAN COULTER
 8.5 INC (USA)
 8.6 BIO-RAD LABORATORIES
 8.7 INC (USA)
 8.8 THERMO FISHER SCIENTIFIC INC (USA)
 8.9 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH (GERMANY)
 8.10 F HOFFMANN-LA ROCHE LTD (SWITZERLAND)
 8.11 RANDOX LABORATORIES LTD (UK)
 8.12 SIEMENS HEALTHINEERS AG (GERMANY)
 8.13 BIOMÉRIEUX
 8.14 INC (FRANCE)
 8.15 OTHERS KEY PLAYER

Chapter 9: Global Therapeutic Drug Monitoring Market By Region
 9.1 Overview
 9.2. North America Therapeutic Drug Monitoring Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Technology
  9.2.4.1 Immunoassays
  9.2.4.2 Chromatography-Spectrometry
  9.2.4.3 Others
  9.2.5 Historic and Forecasted Market Size By Product
  9.2.5.1 Consumables
  9.2.5.2 Equipment
  9.2.6 Historic and Forecasted Market Size By Drug Class
  9.2.6.1 Antiepileptic Drugs
  9.2.6.2 Antiarrhythmic Drugs
  9.2.6.3 Immunosuppressant Drugs
  9.2.6.4 Antibiotic Drugs
  9.2.6.5 Others
  9.2.7 Historic and Forecasted Market Size By End Users
  9.2.7.1 Hospital
  9.2.7.2 Diagnostic labs
  9.2.7.3 Research & Academic Institutes
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Therapeutic Drug Monitoring Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Technology
  9.3.4.1 Immunoassays
  9.3.4.2 Chromatography-Spectrometry
  9.3.4.3 Others
  9.3.5 Historic and Forecasted Market Size By Product
  9.3.5.1 Consumables
  9.3.5.2 Equipment
  9.3.6 Historic and Forecasted Market Size By Drug Class
  9.3.6.1 Antiepileptic Drugs
  9.3.6.2 Antiarrhythmic Drugs
  9.3.6.3 Immunosuppressant Drugs
  9.3.6.4 Antibiotic Drugs
  9.3.6.5 Others
  9.3.7 Historic and Forecasted Market Size By End Users
  9.3.7.1 Hospital
  9.3.7.2 Diagnostic labs
  9.3.7.3 Research & Academic Institutes
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Therapeutic Drug Monitoring Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Technology
  9.4.4.1 Immunoassays
  9.4.4.2 Chromatography-Spectrometry
  9.4.4.3 Others
  9.4.5 Historic and Forecasted Market Size By Product
  9.4.5.1 Consumables
  9.4.5.2 Equipment
  9.4.6 Historic and Forecasted Market Size By Drug Class
  9.4.6.1 Antiepileptic Drugs
  9.4.6.2 Antiarrhythmic Drugs
  9.4.6.3 Immunosuppressant Drugs
  9.4.6.4 Antibiotic Drugs
  9.4.6.5 Others
  9.4.7 Historic and Forecasted Market Size By End Users
  9.4.7.1 Hospital
  9.4.7.2 Diagnostic labs
  9.4.7.3 Research & Academic Institutes
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Therapeutic Drug Monitoring Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Technology
  9.5.4.1 Immunoassays
  9.5.4.2 Chromatography-Spectrometry
  9.5.4.3 Others
  9.5.5 Historic and Forecasted Market Size By Product
  9.5.5.1 Consumables
  9.5.5.2 Equipment
  9.5.6 Historic and Forecasted Market Size By Drug Class
  9.5.6.1 Antiepileptic Drugs
  9.5.6.2 Antiarrhythmic Drugs
  9.5.6.3 Immunosuppressant Drugs
  9.5.6.4 Antibiotic Drugs
  9.5.6.5 Others
  9.5.7 Historic and Forecasted Market Size By End Users
  9.5.7.1 Hospital
  9.5.7.2 Diagnostic labs
  9.5.7.3 Research & Academic Institutes
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Therapeutic Drug Monitoring Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Technology
  9.6.4.1 Immunoassays
  9.6.4.2 Chromatography-Spectrometry
  9.6.4.3 Others
  9.6.5 Historic and Forecasted Market Size By Product
  9.6.5.1 Consumables
  9.6.5.2 Equipment
  9.6.6 Historic and Forecasted Market Size By Drug Class
  9.6.6.1 Antiepileptic Drugs
  9.6.6.2 Antiarrhythmic Drugs
  9.6.6.3 Immunosuppressant Drugs
  9.6.6.4 Antibiotic Drugs
  9.6.6.5 Others
  9.6.7 Historic and Forecasted Market Size By End Users
  9.6.7.1 Hospital
  9.6.7.2 Diagnostic labs
  9.6.7.3 Research & Academic Institutes
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Therapeutic Drug Monitoring Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Technology
  9.7.4.1 Immunoassays
  9.7.4.2 Chromatography-Spectrometry
  9.7.4.3 Others
  9.7.5 Historic and Forecasted Market Size By Product
  9.7.5.1 Consumables
  9.7.5.2 Equipment
  9.7.6 Historic and Forecasted Market Size By Drug Class
  9.7.6.1 Antiepileptic Drugs
  9.7.6.2 Antiarrhythmic Drugs
  9.7.6.3 Immunosuppressant Drugs
  9.7.6.4 Antibiotic Drugs
  9.7.6.5 Others
  9.7.7 Historic and Forecasted Market Size By End Users
  9.7.7.1 Hospital
  9.7.7.2 Diagnostic labs
  9.7.7.3 Research & Academic Institutes
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research